, Volume 19, Issue 4, pp 257–260 | Cite as

Novel case of neurodegeneration with brain iron accumulation 4 (NBIA4) caused by a pathogenic variant affecting splicing

  • Peter SparberEmail author
  • Andrey Marakhonov
  • Alexandra Filatova
  • Inna Sharkova
  • Mikhail Skoblov
Short Communication


Neurodegeneration with brain iron accumulation type 4 (NBIA4) also known as MPAN (mitochondria protein-associated neurodegeneration) is a rare neurological disorder which main feature is brain iron accumulation most frequently in the globus pallidus and substantia nigra. Whole exome sequencing (WES) in a 12-year-old patient revealed 2 variants in the C19orf12 gene, a previously reported common 11 bp deletion c.204_214del11, p.(Gly69Argfs*10) and a novel splicing variant c.193+5G>A. Functional analysis of novel variant showed skipping of the second exon, resulting in a formation of a truncated nonfunctional protein. This is the first functionally annotated pathogenic splicing variant in NBIA4.


MPAN NBIA C19orf12 Neurodegeneration Iron accumulation Functional analysis Splicing 


Compliance with ethical standards

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.


  1. 1.
    Di Meo I, Tiranti V (2018) Classification and molecular pathogenesis of NBIA syndromes. Eur J Paediatr Neurol 22(2):272–284CrossRefPubMedGoogle Scholar
  2. 2.
    Gregory, A. and S. Hayflick, Neurodegeneration with brain iron accumulation disorders overview. 2014Google Scholar
  3. 3.
    Jaberi E et al (2016) Identification of mutation in GTPBP2 in patients of a family with neurodegeneration accompanied by iron deposition in the brain. Neurobiol Aging 38:216 e11–216 e18CrossRefGoogle Scholar
  4. 4.
    Orphanet Report Series - Prevalence of rare diseases: Bibliographic data - January 2018 - Number 1. 2018Google Scholar
  5. 5.
    Hartig M et al (2013) Mitochondrial membrane protein-associated neurodegeneration (MPAN). Int Rev Neurobiol 110:73–84CrossRefPubMedGoogle Scholar
  6. 6.
    Monfrini E, Melzi V, Buongarzone G, Franco G, Ronchi D, Dilena R, Scola E, Vizziello P, Bordoni A, Bresolin N, Comi GP, Corti S, di Fonzo A (2018) A de novo C19orf12 heterozygous mutation in a patient with MPAN. Parkinsonism Relat Disord 48:109–111CrossRefPubMedGoogle Scholar
  7. 7.
    Dogu O, Krebs CE, Kaleagasi H, Demirtas Z, Oksuz N, Walker RH, Paisán-Ruiz C (2013) Rapid disease progression in adult-onset mitochondrial membrane protein-associated neurodegeneration. Clin Genet 84(4):350–355CrossRefPubMedGoogle Scholar
  8. 8.
    Hartig MB, Iuso A, Haack T, Kmiec T, Jurkiewicz E, Heim K, Roeber S, Tarabin V, Dusi S, Krajewska-Walasek M, Jozwiak S, Hempel M, Winkelmann J, Elstner M, Oexle K, Klopstock T, Mueller-Felber W, Gasser T, Trenkwalder C, Tiranti V, Kretzschmar H, Schmitz G, Strom TM, Meitinger T, Prokisch H (2011) Absence of an orphan mitochondrial protein, c19orf12, causes a distinct clinical subtype of neurodegeneration with brain iron accumulation. Am J Hum Genet 89(4):543–550CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Hogarth P, Gregory A, Kruer MC, Sanford L, Wagoner W, Natowicz MR, Egel RT, Subramony SH, Goldman JG, Berry-Kravis E, Foulds NC, Hammans SR, Desguerre I, Rodriguez D, Wilson C, Diedrich A, Green S, Tran H, Reese L, Woltjer RL, Hayflick SJ (2013) New NBIA subtype: genetic, clinical, pathologic, and radiographic features of MPAN. Neurology 80(3):268–275CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Richards S et al (2015) Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 17(5):405–424CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Pereverzev AP, Gurskaya NG, Ermakova GV, Kudryavtseva EI, Markina NM, Kotlobay AA, Lukyanov SA, Zaraisky AG, Lukyanov KA (2015) Method for quantitative analysis of nonsense-mediated mRNA decay at the single cell level. Sci Rep 5:7729CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Drecourt A, Babdor J, Dussiot M, Petit F, Goudin N, Garfa-Traoré M, Habarou F, Bole-Feysot C, Nitschké P, Ottolenghi C, Metodiev MD, Serre V, Desguerre I, Boddaert N, Hermine O, Munnich A, Rötig A (2018) Impaired transferrin receptor palmitoylation and recycling in neurodegeneration with brain iron accumulation. Am J Hum Genet 102(2):266–277CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Selikhova M, Fedotova E, Wiethoff S, Schottlaender LV, Klyushnikov S, Illarioshkin SN, Houlden H (2017) A 30-year history of MPAN case from Russia. Clin Neurol Neurosurg 159:111–113CrossRefPubMedGoogle Scholar
  14. 14.
    Zakharova EY, Rudenskaya GE (2014) A new form of hereditary neurodegeneration with brain iron accumulation: clinical and molecular-genetic characteristics. Zh Nevropatol Psikhiatr Im S S Korsakova 114(1):4–12Google Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Research Centre for Medical Genetics Moskvorechie 1MoscowRussia
  2. 2.School of BiomedicineFar Eastern Federal UniversityVladivostokRussia

Personalised recommendations